Google Health App Introduces New Health Guardian Features for Pixel Watch Users
The Google Health app has introduced a suite of new Health Guardian features specifically for Pixel Watch users, enabling them to prioritize their well-being more effectively. These features include the ability to track blood pressure trends, insulin resistance trends, and sleep breathing quality metrics, which will be available starting this week for users of Pixel Watch 3, 4, and 5. The first reports on these trends are expected to be delivered in early October. Additionally, Fitbit Air users will have access to insulin resistance and blood pressure trend tracking through a Google Health Premium subscription later this year.
These Health Guardian features are backed by clinical research and are designed to operate continuously in the background, monitoring subtle physiological changes over time. A notable addition is the Breathing Emergency Detection feature, available for Pixel Watch 4 and 5 users in select European countries. This feature is intended to automatically alert emergency services if it detects severe drops in blood oxygen levels.
It is important to note that the availability of these features may vary based on region and device compatibility, and some may require a subscription. The blood pressure and insulin resistance trend insights are intended solely for general wellness and informational purposes. They are not designed to diagnose, treat, cure, or prevent any medical conditions, nor should they replace professional medical advice. Users are advised to consult healthcare professionals for any medical questions.
The insights regarding blood pressure and insulin resistance trends will be provided on the first of each month, contingent on users having sufficient data collected during that month. Specifically, at least seven days of data are required for insulin resistance, while blood pressure tracking necessitates a minimum of five consecutive days of readings.
Lastly, it is worth mentioning that the Breathing Emergency Detection feature has not been evaluated by the FDA, although it has received CE marking in the EU and is available in select markets. Users should remain aware of the limitations of these tools and consult with healthcare providers regarding any health-related concerns.




